US Broker Ratings

Neuropace, Inc. (NPCE) Stock Analysis: A Healthcare Innovator with a Promising 28% Potential Upside

Investors looking to tap into the burgeoning healthcare sector might want to take a closer look at Neuropace, Inc. (NASDAQ: NPCE), a trailblazer in the medical device industry. With its..

Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Exploring a 35% Upside Potential Amid Biotech Innovations

Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a clinical-stage biotechnology company, is attracting significant investor attention due to its promising pipeline aimed at treating severe autoimmune diseases. With a current market capitalization..

Arbutus Biopharma (ABUS) Stock Analysis: Unveiling an 11.5% Upside in the Biotech Sector

Arbutus Biopharma Corporation (NASDAQ: ABUS) stands as a significant player in the biotechnology sector, capturing investor attention with its focus on developing novel therapeutics for infectious diseases. With a current..

AbCellera Biologics Inc. (ABCL)

⚠️ No article content returned.

..

Taysha Gene Therapies, Inc. (TSHA) Investor Outlook: Exploring a Potential 94% Upside in the Biotech Arena

Taysha Gene Therapies, Inc. (TSHA), a clinical-stage biotechnology company, is gaining attention in the healthcare sector with its ambitious pursuit of adeno-associated virus-based gene therapies. Headquartered in Dallas, Texas, and..

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Exploring a 38.82% Upside Potential in the Biotech Sector

ArriVent BioPharma, Inc. (AVBP), a clinical-stage biopharmaceutical company, is making waves in the biotechnology industry with its promising pipeline of cancer therapies. With a market capitalization of $1.31 billion, ArriVent..

Spyre Therapeutics, Inc. (SYRE) Investor Outlook: Exploring a 22% Potential Upside in the Biotech Sector

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a promising player in the biotechnology sector, stands out with a compelling potential upside of 22.53%, catching the attention of investors seeking opportunities in the..

Simulations Plus, Inc. (SLP) Stock Analysis: Exploring a 67.61% Potential Upside in Healthcare Software Solutions

Simulations Plus, Inc. (NASDAQ: SLP) stands prominently in the healthcare sector, specializing in health information services. This U.S.-based company has carved a niche in the drug discovery and development sector..

Replimune Group, Inc. (REPL) Stock Analysis: Evaluating a 59.82% Potential Upside in Oncolytic Immunotherapy

Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company, is pioneering the development of oncolytic immunotherapies designed to activate the immune system against cancer. While its innovative approach to cancer..

Immunome, Inc. (IMNM) Stock Analysis: Exploring a 52.79% Potential Upside with Strong Buy Consensus

Immunome, Inc. (NASDAQ: IMNM), a burgeoning player in the biotechnology sector, is capturing the attention of investors with its promising therapeutic innovations and a robust consensus of buy ratings. With..

InMode Ltd. (INMD) Stock Analysis: Unveiling an 18.63% Potential Upside in the Medical Devices Sector

InMode Ltd. (NASDAQ: INMD), a prominent player in the healthcare sector, specifically within the medical devices industry, is headquartered in Yokne’am, Israel. Known for its innovative approach to minimally invasive..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring the 136% Potential Upside for Biotech Investors

Gyre Therapeutics, Inc. (NASDAQ: GYRE) is capturing attention in the healthcare sector, particularly among biotechnology investors, due to its promising portfolio and substantial potential upside. With a market capitalization of..

Cronos Group Inc. (CRON) Stock Analysis: Navigating a 47% Revenue Surge Amid Market Challenges

Cronos Group Inc. (NASDAQ: CRON), a prominent player in the cannabinoid industry, is capturing investor attention despite a challenging market landscape. With a notable 47% revenue growth, the company is..

Geron Corporation (GERN) Stock Analysis: Exploring a 101% Potential Upside in Biotech

Geron Corporation (NASDAQ: GERN), a notable player in the biotechnology sector, offers an intriguing investment proposition with a potential upside of 101.18% according to analyst targets. With a current market..

Phibro Animal Health Corporation (PAHC) Stock Analysis: An Investor’s Perspective on Growth Potential and Market Position

Phibro Animal Health Corporation (NASDAQ: PAHC), a significant player in the healthcare sector, specifically in the drug manufacturing of specialty and generic products, is attracting investor attention with its robust..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: Unveiling a Potential 187.53% Upside in the Biotechnology Sector

In the ever-evolving biotechnology sector, Niagen Bioscience, Inc. (NASDAQ: NAGE) stands out with its innovative approach to healthy aging and a remarkable potential upside of 187.53% based on current analyst..

uniQure N.V. (QURE) Stock Analysis: Navigating a 129.74% Potential Upside in Biotechnology

Investors with a keen eye on the biotechnology sector might find uniQure N.V. (NASDAQ: QURE) an intriguing prospect, particularly considering its potential upside of 129.74%. As a Dutch company specializing..

AMN Healthcare Services Inc (AMN) Stock Analysis: Navigating Growth Amidst Market Volatility

AMN Healthcare Services Inc (NYSE: AMN), a prominent player in the U.S. healthcare sector, stands at a pivotal juncture. Known for its technology-enabled workforce solutions, AMN serves a broad spectrum..

Zymeworks Inc. (ZYME) Stock Analysis: Robust Buy Ratings and Promising Upside Potential

Zymeworks Inc. (ZYME), a prominent player in the biotechnology sector, is capturing investor attention with its innovative approach to developing biotherapeutics for cancer, inflammation, and autoimmune diseases. With a current..

Arcus Biosciences, Inc. (RCUS) Investor Outlook: Strong Buy Ratings and a 44.98% Upside Potential

Arcus Biosciences, Inc. (NASDAQ: RCUS), a prominent player in the biotechnology sector, is drawing significant attention from investors due to its promising pipeline of cancer therapies and a notably high..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds